- News Home
10 April 2014 11:44 am ,
Vol. 344 ,
The Pyrenean ibex, an impressive mountain goat that lived in the central Pyrenees in Spain, went extinct in 2000. But a...
Tight budgets are forcing NASA to consider turning off one or more planetary science projects that have completed their...
Ebola is not a stranger to West Africa—an outbreak in the 1990s killed chimpanzees and sickened one researcher. But the...
In an as-yet-unpublished report, an international panel of geoscientists has concluded that a pair of deadly...
Tropical disease experts tried and failed before to eradicate yaws, a rare disfiguring disease of poor countries. Now,...
Since 2002, researchers have reported that agricultural communities in the hot and humid Pacific Coast of Central...
Balkan endemic kidney disease surfaced in the 1950s and for decades defied attempts to finger the cause. It occurred...
- 10 April 2014 11:44 am , Vol. 344 , #6180
- About Us
Five More Companies Join NIH's Drug Reuse Program
12 June 2012 2:20 pm
The National Institutes of Health (NIH) today unveiled the details of its $20 million program for finding new uses for abandoned drugs—along with five more participating companies. The program's expansion brings to 58 the number of shelved compounds that academic researchers can test for new uses.
Discovering New Therapeutic Uses for Existing Molecules, announced in early May, is the first major initiative from NIH's new National Center for Advancing Translational Science (NCATS). The idea is to give academic researchers access to compounds that made it through safety testing but were dropped by companies for business reasons or because they didn't work on a specific disease. Initially, three companies—Pfizer, AstraZeneca, and Eli Lilly—offered to share 24 compounds.
Now Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, and Janssen Pharmaceuticals have signed on, bringing the number of compounds to 58. NIH has posted a table of the compounds that links to one-page fact sheets about the drugs that include the mechanism of action and summary clinical results. NIH is also taking preapplications (due 14 August) for the program's 2- to 3-year grants.
The program has gotten a mixed response from pharma experts; some think the chances of finding new uses for the compounds are slim. Others are supportive but have concerns about the template legal agreements NIH has developed for companies and academics. In this 1 June letter to NCATS, the Association of American Medical Colleges says the templates should be revised because they "require academic partners to share data and other information with firms providing the compounds even where IP [intellectual property] rights do not necessarily extend to that information."